It's possible you might see an early boom in the uptake of Nextstellis. However, it may take a few quarters to see the momentum in Nextstellis sales. Nuvaring is still bubbling away in the background and could see approval anytime, with the Mayne (Mithra) product superior to the generics that beat them to market. There is also the rebalancing of the whole portfolio away from generics being the biggest piece of the earnings pie – generics being the thorn in the side. The only way is up.
MYX Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)